These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22421924)

  • 1. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
    Kosinski JR; Hubert J; Carrington PE; Chicchi GG; Mu J; Miller C; Cao J; Bianchi E; Pessi A; Sinharoy R; Marsh DJ; Pocai A
    Obesity (Silver Spring); 2012 Aug; 20(8):1566-71. PubMed ID: 22421924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
    Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling oxyntomodulin, GLP1's enigmatic brother.
    Pocai A
    J Endocrinol; 2012 Dec; 215(3):335-46. PubMed ID: 23019069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
    Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
    J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.
    Cai X; Li C; Zhou J; Dai Y; Avraham Y; Sun L; Liu C; Tong J; Wang Y; Bi X; He L; Huang W; Qian H
    Bioorg Chem; 2020 Jan; 95():103538. PubMed ID: 31901754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
    Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
    Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
    Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
    Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
    Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.
    Bianchi E; Carrington PE; Ingallinella P; Finotto M; Santoprete A; Petrov A; Eiermann G; Kosinski J; Marsh DJ; Pocai A; SinhaRoy R; Pessi A
    Bioorg Med Chem; 2013 Nov; 21(22):7064-73. PubMed ID: 24094437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action and therapeutic potential of oxyntomodulin.
    Pocai A
    Mol Metab; 2014 Jun; 3(3):241-51. PubMed ID: 24749050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of Potent and Proteolytically Stable Oxyntomodulin Analogs.
    Muppidi A; Zou H; Yang PY; Chao E; Sherwood L; Nunez V; Woods AK; Schultz PG; Lin Q; Shen W
    ACS Chem Biol; 2016 Feb; 11(2):324-8. PubMed ID: 26727558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents.
    Liu YL; Ford HE; Druce MR; Minnion JS; Field BC; Shillito JC; Baxter J; Murphy KG; Ghatei MA; Bloom SR
    Int J Obes (Lond); 2010 Dec; 34(12):1715-25. PubMed ID: 20531351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
    Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.